Clinical Trials | June 09, 2026
AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
